CytoMed Therapeutics Limited

NasdaqCM GDTC

CytoMed Therapeutics Limited Interest Coverage Ratio for the year ending December 31, 2023

CytoMed Therapeutics Limited Interest Coverage Ratio is NA for the year ending December 31, 2023. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

CytoMed Therapeutics Limited Interest Coverage Ratio for the year ending December 31, 2022 was -15.08, a 8.37% change year over year.
CytoMed Therapeutics Limited Interest Coverage Ratio for the year ending December 31, 2021 was -16.46, a -38.26% change year over year.
CytoMed Therapeutics Limited Interest Coverage Ratio for the year ending December 31, 2020 was -11.91.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqCM: GDTC

CytoMed Therapeutics Limited

CEO	Mr. Chee Kong Choo
IPO Date	April 14, 2023
Location	Singapore
Headquarters	1 Commonwealth Lane, No. 08-22
Employees	28
Sector	Healthcare
Industries Biotechnology 3D Printing Robotics

Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

Key trends

Past 5 years